MORSE Consulting’s Most-Favored Nation (MFN) Report:

The Canadian Deep Dive

Insights into navigating MFN pricing challenges and implications for drug launches in Canada

Built from MORSE’s direct experience advising pharmaceutical companies on Canadian pricing and reimbursement strategy, this report equips your team with the insights needed to navigate MFN pressure confidently — whether you’re planning a new launch, managing an existing portfolio, or preparing for the next round of pCPA negotiations.

What MORSE'S Report Covers:

Current MFN agreement status: detailed breakdown of all 17 manufacturer agreements, timelines, and commitments
TrumpRx direct-to-consumer model analysis and early market data
MFN pricing models explained: practical guidance on GENEROUS, GLOBE, and GUARD pricing conversions across jurisdictions
Canadian pricing constraints: why “just raise prices” won’t work — gross to net implications, PMPRB guidelines, PLA restrictions, and the generic pricing paradox
pCPA’s current approach: active monitoring of MFN-affected negotiations, including real-time status tracking
Key considerations for innovative launch pricing under MFN pressure
Implications for list-to-net dynamics, payer expectations, and long-term Canadian market impact

Request Vetted Access

This report is only available to pharmaceutical companies to assist with their reimbursement forecasting and planning.

We're committed to your privacy. MORSE may use the information you provide to us to contact you about our relevant content and services. Your name, address and all other personal information will not be sold or given to any other organization or list distributor. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

Context is essential. Action is critical.

Strategic Comparison	Global White Paper	MORSE Canadian Deep Dive
Focus Area	(Free Resource)	(Paid Strategic Report)
Jurisdictional Scope	8 International Markets	Exclusive Canadian Focus
Agreement Analytics	General Benchmarking	Audit of all 17 MFN Agreements
Regulatory Depth	Global MFN Overview	pCPA & PMPRB Specific Guidance
Market Intelligence	Reference Pricing Models	TrumpRx & Generic Pricing Paradox
Decision Support	Baseline Context	Actionable Risk Modeling & ROI
Access Points	Standard Access Back to Free Paper	Premium Strategic Access Get Full Strategic Access

MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.

Most Favored Nation - Drug Launches in Canada